In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.

We developed a humanized bifunctional antibody (mPEG×tumor marker),the anti-PEG end can be non-covalently modified to bind any PEGylated nano-druga contrast agent by one-step "formulation". The non-covalent binding solved the problems of chemical modification such as the masking of the antibody binding site, heterogeneity, drug instability. The other end of the bifunctional antibody can specifical

Cancer is the first leading cause of death in Taiwan. Targeted therapy allows the cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. This report contains two invention technologies which combined early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis)the treated with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA) to inhibit the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers.